NCT00802672已完成3 期
A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Padagis LLC
- 入组人数
- 561
- 主要终点
- Proportion of Subjects in Each Treatment Group With Therapeutic Success
研究概览
简要总结
The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox Olamine Cream (Test Product) and Ciclopirox Cream 0.77% (Reference Product) in the treatment of subjects with tinea pedis, and to show the superiority of the active treatments over that of the vehicle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 10 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female at least 10 years of age, and otherwise healthy
- •Clinically and mycologically confirmed diagnosis of symptomatic tinea pedis
- •In good health with no clinically significant disease that might have interfered with study evaluations
- •Study participant or legal guardian was willing and able to read and sign an IRB approved ICF, which included agreement to comply with all study requirements as indicated in the protocol. For subjects 10 to 17 years of age, an assent form for minors was completed.
排除标准
- •History of hypersensitivity or allergy to ciclopirox
- •Had any skin condition that would interfere with the diagnosis or assessment of tinea pedis
- •Had a history of dermatophyte infecton unresponsive to antifungal treatment
- •Had a history of alcoholism, drug abuse, or problems that would likely have made the subject unreliable for the study
- •Had any condition or used any medication that, in the opinion of the Investigator, might have interfered with the conduct or results of the study or placed the prospective subject at increased risk
- •Was unwilling to sign the informed consent
- •Female who was pregnant or lactating
研究组 & 干预措施
Test Product
Experimental
Ciclopirox Olamine Cream 0.77%
干预措施: Ciclopirox Olamine Cream (Drug)
Reference Product
Active Comparator
Loprox Cream 0.77%
干预措施: Loprox Cream 0.77% (Drug)
Vehicle Product
Placebo Comparator
placebo of test product
干预措施: Placebo (Drug)
结局指标
主要结局
Proportion of Subjects in Each Treatment Group With Therapeutic Success
时间窗: 6 weeks
Both Mycological Cure (KOH wet mount negative and fungal culture negative) and Clinical Cure were required to achieve Therapeutic Success
次要结局
- Proportion of Subjects With Mycological Cure(6 weeks)
- Proportion of Subjects With Clinical Cure(6 weeks)
研究者
相似试验
已完成
1 期
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea PedisTinea PedisNCT01580878Taro Pharmaceuticals USA707
已完成
1 期
A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.Secondarily Infected Traumatic Skin LesionsNCT01876550Taro Pharmaceuticals USA1,902
已完成
3 期
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)Postoperative PainNCT00092339Merck Sharp & Dohme LLC125
已完成
3 期
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic HypersomniaIdiopathic HypersomniaNCT05156047Harmony Biosciences, LLC214
已完成
1 期
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®Healthy SubjectsNCT04027803Biocad78